Brentuximab is an anti-CD30 monoclonal antibody frequently used in patients with Hodgkin lymphoma, anaplastic large-cell lymphoma, and other CD30-positive lymphomas [17]. The patient experienced a complete response to this combined immunotherapy. This evidence concerns the gene TNFRSF8 and lymphoma.